CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback